Although initially the inhibitory properties of orlistat were demonstrated for pancreatic lipase, a large survey of a number of tumor and normal cell lines has lead to the conclusion that orlistat has no other targets than FASN in tumor cells, and that has minimal effects on the normal cells. Here, FASN is linked to neoplasm.